REFERENCES
1) Ferguson JL, Turner SP. Bone cancer: diagnosis and treatment
principles. Am Fam Physician 2018; 98(4):205-213.
2) Zhang Y, Yang J, Zhao N, et al. Progress in the chemotherapeutic
treatment of osteosarcoma (Review). Oncology Letters 2018;16:6228-6237.
3) Zhang L, Zhou X, Liu X, et al. Advances in multi-therapies for the
treatment of Ewing’s sarcoma. Transl Surg 2017;2:14-8. 4) Fukushima T,
Ogura K, Akiyama T, et al. Descriptive epidemiology and outcomes of bone
sarcomas in adolescent and young adult patients in Japan. BMC
Musculoskeletal Disorders 2018;19:297. 5) Baxter NN, Daly C, Gupta S, et
al. The Initiative to Maximize Progress in Adolescent and Young Adult
Cancer Therapy (IMPACT) Cohort Study: a population-based cohort of young
Canadians with cancer. BMC Cancer 2014;14:805. 6) De P, Ellison LF, Barr
RD, et al. Canadian adolescents and young adults with cancer:
opportunity to improve coordination and level of care. CMAJ 2011;
183(3): E194-197. 7) Gupta S, Pole JD, Baxter NN, et al. The effect of
adopting pediatric protocols in adolescents and young adults with acute
lymphoblastic leukemia in pediatric vs adult centers: An IMPACT Cohort
study. Cancer Med 2019;8:2095‐2103. 8) Gupta S, Baxter NN, Pole J, et
al. Outcome Among Adolescents and Young Adults with Acute Myeloid
Leukemia at Pediatric Versus Adult Centers: A Population-Based Study
Using the IMPACT Cohort. Blood 2019;134 (Supplement-1): 4749. 9) Gupta
S, Baxter NN, Hodgson D, et al. Treatment patterns and outcomes in
adolescence and young adults with Hodgkin lymphoma in pediatric versus
adult centers: An IMPACT Cohort Study. Cancer Med 2020;9:6933– 6945.
10) Henderson TO, Parsons SK, Wroblewski KE. Outcomes in Adolescents and
Young Adults With Hodgkin Lymphoma Treated on US Cooperative Group
Protocols: An Adult Intergroup (E2496) and Children’s Oncology Group
(COG AHOD0031) Comparative Analysis. Cancer 2018;124:136-44. 11) Pole
JD, Alibhai SMH, Ethier MC, et al. Adolescents with acute lymphoblastic
leukemia treated at pediatric versus adult hospitals. Annals of Oncology
2013;24: 801- 806. 12) Bleyer A. The quid pro quo of pediatric versus
adult services for older adolescent cancer patients. Pediatr Blood
Cancer 2010;54:238-241. 13) Howell DL, Ward KC, Austin HD, et al. Access
to Pediatric Cancer Care by Age, Race, and Diagnosis, and Outcomes of
Cancer Treatment in Pediatric and Adolescent Patients in the State of
Georgia. J Clin Oncol 2007; 25:4610-4615. 14) Mitchell AE, Scarcella DL,
Rigutto GL, et al. Cancer in adolescents and young adults: treatment and
outcome in Victoria. MJA 2004;180:59-62. 15) Furlong W, Rae C, Greenberg
ML, et al. Surveillance and survival among adolescents and young adults
with cancer in Ontario, Canada. Int. J. Cancer 2012;131:2660–2667. 16)
Gupta AA, Pappo A, Saunders N, et al. Clinical outcome of children and
adults with localized Ewing sarcoma. Impact of chemotherapy dose and
timing of local therapy. Cancer 2010;116 (13): 3189-94. 17) Lethaby CD,
Picton S, Kinsey SE, et al. A systematic review of time to diagnosis in
children and young adults with cancer. Arch Dis Child 2013;98:349-355.
18) Schnurr C, Pippan M, Steutzer H, et al. Treatment delay of bone
tumors, compilation of a sociodemographic risk profile: A retrospective
study. BMC Cancer 2008; 8: 22. 19) Goyal S, Roscoe J, Ryder WDJ, et al.
Symptom interval in young people with bone cancer. European Journal of
Cancer 2004; 40: 2280-2286. 20) Goedhart LM, Gerbers JG, Ploegmaker JJW,
et al. Delay in diagnosis and its effect on clinical outcome in
high-grade sarcoma of bone: a referral oncological study. Orthopaedic
Surgery 2016;8:122-128. 21) Brasme J, Chalumeau M, Oberlin O, et al.
Time to diagnosis of Ewing tumors in children and adolescents is not
associated with metastasis and survival: A prospective multicenter study
of 436 patients. J Clin Oncol 2014; 32: 1935-1940. 22) Agha M, DiMonte
B, Greenberg M. Incidence trends and projections for childhood cancer in
Ontario. Int J Cancer 2006;118:2809-2815. 23) Greenberg ML, Barr RD,
Dimonte B, et al. Childhood cancer registries in Ontario, Canada:
lessons learned from a comparison of two registries. Int J Cancer
2003;105:88-91. 24) Gupta S, Nathan PC, Baxter NN, et al. Validity of
administrative data in identifying cancer-related events in adolescents
and young adults: A population-based study using the IMPACT Cohort. Med
Care 2018; 56: e32-e38. 25) Kralj B. “Measuring ‘rurality’ for purposes
of health-care planning: an empirical measure for Ontario”. Ontario
Medical Review. October 2000. 26) Green DM, Nolan VG, Goodman PJ, et al.
The Cyclophosphamide Equivalent Dose as an approach for quantifying
alkylating agent exposure. A report from the Childhood Cancer Survivor
Study. Pediatr Blood Cancer 2014; 61(1): 53-67. 27) Sæter G, Elomaa I,
Wahlqvist Y, et al. Prognostic factors in bone sarcomas. Acta
Orthopaedica Scandinavica 1997; 68:sup273, 156-160,
DOI:10.1080/17453674.1997.11744723. 28) Petrilli AS, Gentil FC, Epelman
S, et al. Increased survival, limb preservation, and prognostic factors
for osteosarcoma. Cancer 1991; 68:733-737. 29) Bielack SS, Kempf-Bielack
B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of
the extremities or trunk: An analysis of 1,702 patients treated on
Neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol
2002; 20:776-790. 30) Boissel N, Auclerc MF, Lheritier V, et al. Should
adolescents with acute lymphoblastic leukemia be treated as old children
or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.
J Clin Oncol 2003, 21 (5): 774-780. 31) Epelman S. The Adolescent and
Young Adult with Cancer: State of the Art-Brain Tumor. Curr Oncol Rep
2013;15:308-316. 32) De Bont JM, Holt Bvd, Dekker AW et al.. Significant
difference in outcome for adolescents with acute lymphoblastic leukemia
treated on pediatric vs adult protocols in The Netherlands. Leukemia
2004; 18: 2032-2035. 33) Ramanujachar R, Richards S, Hann I et al.
Adolescents with acute lymphoblastic leukaemia: outcome on UK National
paediatric (ALL97) and adult (UKALLXII/ E2993) trials. Pediatric Blood
Cancer 2007; 48: 254-261. 34) Basile P, Greengard E, Weigel B, Spector
L. Prognostic factors for development of subsequent metastases in
localized osteosarcoma: A systematic review and identification of
literature gaps. Sarcoma 2020 Mar 18;2020:7431549.
doi:10.1155/2020/7431549. eCollection 2020. 35) Stachelek GC, Ligon JA,
Vogel J, et al. Predictors of recurrence and patterns of initial failure
in localized Ewing sarcoma: A contemporary 20-Year Experience. Sarcoma,
volume 2021 |Article ID 6681741 |
https://doi.org/10.1155/2021/6681741